Mirikizumab: A promising breakthrough in Crohn's disease treatment
Mirikizumab, based on the VIVID-1 trial outcomes, is a promising addition to CD therapy. It demonstrated significant clinical responses and remission rates, warranting further research on its long-term efficacy and safety. Updating professional guidelines and addressing affordability will ensure broader access and improved management of CD.
Authors
- Muaaz Aslam
- Hamza Irfan (ORCID: https://orcid.org/0000-0002-0967-7523)
- Mohammad Haris Ali (ORCID: https://orcid.org/0009-0001-5076-1364)
Institutions
- Shaikh Zayed Postgraduate Medical Institute (PK)
Publication Details
- Journal
- Health Science Reports
- Published
- 2024-08-01
- DOI
- https://doi.org/10.1002/hsr2.2294
- Citations
- 5
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 2.75